Back to List View Graph View

Liraglutide

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) developed as an acylated analogue of the endogenous incretin hormone GLP-1.

Where the papers sit

16 papers from the last 6 months study liraglutide directly · updated from PubMed 16 Nov 2026

  • GLP-1 Pharmacology and Clinical Effects

    GLP-1R activation is being examined for appetite control, delayed gastric emptying, body weight and obesity treatment. Clinical studies address adolescents, post-bariatric patients and background glucose-lowering therapy, while experimental studies examine gut microbiota, gut-brain signaling and the brain-kidney axis. Protein studies instead track oligomer interconversion and fibril dissociation. The shared subject is broad drug biology, with no single clinical or mechanistic direction dominating.

    8 papers · 50%

  • Metabolic and Cardiovascular Benefits

    Liraglutide’s metabolic effects are expanding from weight and glucose control toward macrophage and tissue remodeling. In obese type 2 diabetes, altered cholesterol handling, ATP-binding cassette subfamily A member 1 and H3K27ac are linked to M2 polarization; liver slices show HSC deactivation and ECM remodeling. Cardiovascular analyses test whether LEADER findings transport to real-world populations, while adolescent studies examine appetite after sleeve gastrectomy. Oral insulin–liraglutide nanoparticles represent an effort to improve delivery.

    5 papers · 31.2%

  • Diabetic Organ Injury Protection

    Diabetic organ injury is being targeted through liraglutide-based anti-inflammatory and mitochondrial protection. In heart injury, sinomenine plus liraglutide restores mitochondrial homeostasis and suppresses CASP1/NLRP3-associated pyroptosis. Lung and muscle protection involves TLR4/NF-κB and Atrogin-1/AMPK signaling, while kidney studies test liraglutide with dapagliflozin. The evidence remains preclinical and centered on streptozotocin-diabetic rat models.

    3 papers · 18.8%

Papers

The 16 papers from the last 6 months that study liraglutide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

GLP-1 Pharmacology and Clinical Effects (8)
  1. Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass. Obesity surgery · 27 Sept 2026 PMID 42802300
  2. A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
  3. Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. Analytical chemistry · 8 Sept 2026 PMID 42708757
  4. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
  5. A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. Science advances · 5 Aug 2026 PMID 42555711
  6. Effects of liraglutide on gut bacterial community dynamics. Microbiology spectrum · 3 Aug 2026 PMID 42545022
  7. Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity (Silver Spring, Md.) · 2 Jul 2026 PMID 42392577
  8. Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell host & microbe · 10 Jun 2026 PMID 42269582
Metabolic and Cardiovascular Benefits (5)
  1. Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation. Journal of molecular histology · 13 Oct 2026 PMID 42870021
  2. Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial. American journal of epidemiology · 22 Sept 2026 PMID 42768735
  3. Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. Pediatric obesity · 1 Aug 2026 PMID 42538646
  4. Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. International journal of biological macromolecules · 13 Jul 2026 PMID 42442575
  5. Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2 Jul 2026 PMID 42392029
Diabetic Organ Injury Protection (3)
  1. A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 19 Sept 2026 PMID 42762056
  2. Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
  3. Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. Molecular biology reports · 26 May 2026 PMID 42189284

By study type

Clinical trials (1)
  1. Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity (Silver Spring, Md.) · 2 Jul 2026 PMID 42392577
Observational studies and case reports (2)
  1. Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass. Obesity surgery · 27 Sept 2026 PMID 42802300
  2. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
Human data, design not indexed (2)
  1. Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. Pediatric obesity · 1 Aug 2026 PMID 42538646
  2. Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2 Jul 2026 PMID 42392029
Preclinical: animal, cell and lab studies (8)
  1. Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation. Journal of molecular histology · 13 Oct 2026 PMID 42870021
  2. A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 19 Sept 2026 PMID 42762056
  3. Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. Analytical chemistry · 8 Sept 2026 PMID 42708757
  4. A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. Science advances · 5 Aug 2026 PMID 42555711
  5. Effects of liraglutide on gut bacterial community dynamics. Microbiology spectrum · 3 Aug 2026 PMID 42545022
  6. Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. International journal of biological macromolecules · 13 Jul 2026 PMID 42442575
  7. Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
  8. Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. Molecular biology reports · 26 May 2026 PMID 42189284
Unclassified: not yet indexed with MeSH (3)
  1. Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial. American journal of epidemiology · 22 Sept 2026 PMID 42768735
  2. A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
  3. Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell host & microbe · 10 Jun 2026 PMID 42269582